**Abstract.** Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma and the incidence of this disease is increasing. The present study aimed to investigate the role of homeobox A6 (HOXA6) in the proliferation and apoptosis of ccRCC cells. Analysis of the GSE6344 dataset and immunohistochemistry revealed that the mRNA and protein expression levels of HOXA6 were suppressed in ccRCC tissues. To evaluate the roles of HOXA6 in cell proliferation and apoptosis, ccRCC cell lines (786-O and 769-P) were transfected with plasmids expressing HOXA6, empty vector, short hairpin (sh)HOXA6 and non-targeting shRNA (NC). Cell Counting Kit-8, colony formation and 5-ethynyl-2'-deoxyuridine staining assays were performed to analyze cell proliferation. In addition, Caspase-Glo and terminal deoxynucleotidyl transferase dUTP nick end labeling assays were performed to detect apoptosis. Furthermore, the cell cycle and apoptotic rates of 786-O and 769-P cells were analyzed by flow cytometry. The results demonstrated that, compared with the empty vector group, the proliferation of 786-O and 769-P cells decreased following HOXA6 overexpression; however, compared with the NC group, cell proliferation increased in the shHOXA6 group. The rate of apoptosis of HOXA6-overexpressing cells was increased compared with the empty vector group, while the rate of apoptosis in the shHOXA6 group was reduced compared with the NC group. In addition, flow cytometry demonstrated that upregulated HOXA6 expression levels could inhibit the cell cycle at the G₀/G₁ phase. Western blotting revealed that the expression levels of phosphoinositide 3-kinase (PI3K), phosphorylated (p)-protein kinase B (Akt), mitogen-activated protein kinase kinase, p-extracellular signal-regulated kinase (ERK) and B-cell lymphoma 2 (Bcl-2) were suppressed in cells overexpressing HOXA6; however, the protein expression levels of phosphatase and tensin homolog, Bcl-2-associated X protein, cleaved caspase-3 and cleaved-poly (ADP-ribose) polymerase were increased compared with the empty vector group. Opposing results were reported for the shHOXA6 group compared with the NC group. In summary, the results demonstrated that HOXA6 suppresses cell proliferation and promotes apoptosis, which may occur via inhibition of the PI3K/Akt/ERK cascade. These findings indicate the role of HOXA6 in ccRCC; however, the underlying mechanism requires further investigation.

**Introduction**

Renal cell carcinoma (RCC) is a common type of cancer worldwide and the incidence of this disease is increasing; the incidence rate of RCC was 10.6/100,000 in 2001, which increased to 12.4/100,000 in 2010 (1,2). Genetic mutations are an important risk factor for the development of RCC (3), which can be detected at early stages. Systemic therapeutic agents, including sunitinib and temsirolimus, have been used to treat RCC (4). The presence of smaller tumors leads to fewer episodes of relapse and improved prognosis (5). Further investigation is required to determine the molecular mechanisms underlying the development of clear cell RCC (ccRCC), the most common type of RCC.

The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway regulates a series of cellular processes, including the cell cycle, proliferation, apoptosis, autophagy and metastasis in various types of cancer (6). The PI3K/Akt signaling pathway serves its role by regulating numerous effectors, particularly factors of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated
kinase (ERK) pathway (7). Due to its key roles in cancer, several potential molecular targets of the PI3K/Akt signaling pathway have been proposed in cancer therapy (8). Furthermore, the PI3K/Akt signaling pathway has been demonstrated to be highly activated and serves a critical role in ccRCC (9,10).

Homeobox A6 (HOXA6) encodes a transcription factor that regulates gene expression and cellular differentiation. HOXA6 has been identified to serve important roles in cell proliferation, differentiation and invasion (11,12). It has been reported that HOXA6 may serve a role in a variety of cancer types; however, the roles of HOXA6 in these cancer types were inconsistent. HOXA6 was observed to be overexpressed in tumor tissues and promoted the progression of cancer (13-15); however, HOXA6 was also determined to be hypermethylated in certain malignancies, indicating reduced expression (16,17). In addition, HOXA6 expression has been reported to be suppressed in breast cancer tissues (18). At present, to the best of our knowledge, extensive research into the roles of HOXA6 in ccRCC has not been conducted. Therefore, the present study aimed to determine the expression profile of HOXA6 in ccRCC. The results revealed that HOXA6 was downregulated in ccRCC; however, the role of HOXA6 in ccRCC and its underlying mechanism requires further investigation. In the present study, the role of HOXA6 in cell proliferation and apoptosis was analyzed, and the association between HOXA6 and the PI3K/Akt signaling pathway in ccRCC was determined.

Materials and methods

Confirmation of HOXA6 expression and survival analysis. Data of HOXA6 mRNA expression was obtained from the GSE6344 dataset (19,20) of the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). The tissue samples included in GSE6344 consisted of ten patient-matched normal renal cortex and ccRCC tissues; five samples were of stage I and five were of stage II ccRCC, according to the TNM staging system (21). All patients were diagnosed with localized disease; stage I tumors were <7 cm and stage II tumors were ≥7 cm. Gene Expression Profiling Interactive Analysis (GEPIA) (22) was performed to determine the association between the mRNA expression levels of HOXA6 and the survival of patients with ccRCC.

Tissue specimens. The present study was approved by the Ethics Committee of The First Affiliated Hospital of Chongqing Medical University (Chongqing, China; approval no. 20185501). Written informed consent was obtained from all patients. A total of 25 pairs of ccRCC and adjacent non-tumor tissue specimens were collected at the Department of Urology between June 2018 and August 2018. The distance between the ccRCC sample and the non-tumor tissue sample was ≥2 cm. Among the 25 patients, 14 patients underwent radical nephrectomy and 11 underwent partial nephrectomy without any pre-operative treatment. The median age of the patients was 53 years (range, 42-78 years).

IHC. Tissues were fixed with 10% formalin at room temperature for 4-6 h. Subsequently, paraffin-embedded tissue sections (5-μm) were dewaxed and rehydrated in 100, 95, 85, 75 and 50% ethanol, boiled at 100°C in 0.01 mol/l sodium citrate buffer (pH 6.0) for 15 min for antigen retrieval and incubated with 3% hydrogen peroxide for 20 min to inhibit endogenous peroxidase activity. Samples were blocked with normal goat serum (reagent B in the SP-9001 kit; OriGene Technologies, Inc.) at 37°C for 30 min and incubated with rabbit anti-HOXA6 (cat. no. bs-11294R, 1:400; BIOSS) overnight at 4°C. A horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG working solution (reagent C in the SP-9001 kit; OriGene Technologies, Inc.) was then applied for 30 min at 37°C. Subsequently, sections were stained at room temperature with 3,3'-diaminobenzidine (OriGene Technologies, Inc.) for 10 sec and hematoxylin (OriGene Technologies, Inc.) for 30 sec at room temperature. Negative control specimens were incubated without anti-HOXA6.

The score criterion was set according to the intensity and extent of the staining in a percentage of positive cells. The intensity scores were as follows: 0, no staining; 1, weak; 2, moderate; and 3, intense. The scores for the extent of staining were as follows: 0, 0%; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. The IHC scores were calculated by multiplying the intensity scores with the extent of staining scores (0-12). IHC scores <3 were defined as low expression, while scores ≥4 were defined as high expression. A light microscope was used to capture the images (magnification, x200 and x400). The ccRCC subtype and IHC scores were confirmed independently by two pathologists.

Cell culture and transfection. The human ccRCC cell lines, 786-O and 769-P, were purchased from the American Type Culture Collection and cultured in RPMI-1640 medium (HyClone; GE Healthcare) containing 10% fetal bovine serum (PAN-Biotech) at 37°C in 5% CO₂.

The plasmids were supplied by GeneCopoeia, Inc., including HOXA6-expressing plasmid, empty vector (term vector; pRecevier-M03), and plasmids containing short hairpin (sh)HOXA6 (5'-CCCTTGTGTCTACACAGTCC-3') and non-targeting shRNA (NC; 5'-GCTTCGCGCCGTAGTCTTA-3'). 786-O and 769-P cells were transfected using Lipofectamine 2000® (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Cells were seeded into a 6-well plate at a density of ~2×10⁵ cells per well, and a total of 4 μg plasmids were added for transfection at 50-75% confluence.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). At 48 h post-transfection, total RNA was extracted from cells using TRIzol® reagent (Thermo Fisher Scientific, Inc.) and reverse transcribed with the GoScript™ Reverse Transcription system (Promega Corporation) at 25°C for 5 min, 42°C for 60 min, 70°C for 15 min and 4°C until the subsequent step. The primers used for qPCR were as follows (15): HOXA6 forward, 5'-TACACCGCTCTACAGACAC-3' and reverse, 5'-CGTGAGAATTGAGCTTGTTT-3'; b-actin forward, 5'-TGGAACGGTGAAGGTGAG-3' and reverse, 5'-AACAAGCGATCTCATATTGGGA-3'. qPCR was performed using the GoTaq qPCR Master
mix (Promega Corporation), with the following thermocycling conditions: 95˚C for 10 min, 40 cycles of 95˚C for 15 sec and 60˚C for 1 min, followed by 95˚C for 15 sec, 60˚C for 1 min and 95˚C for 15 sec, according to the manufacturer's protocol. Data were analyzed using the 2^−∆∆Cq method (23).

Western blotting. At 72 h post-transfection, total proteins were extracted from cells using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) and the protein concentration was measured via the bicinchoninic acid method. Proteins (40 µg) were separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. Subsequently, the PVDF membrane was blocked with 5% skim milk at room temperature for 2 h and incubated with primary antibodies at 4˚C overnight. The membrane was then incubated with an HRP-conjugated secondary antibody (1:1,000; cat. no. 4257; Cell Signaling Technology, Inc.), anti-Akt (1:1,000; cat. no. 4691; Cell Signaling Technology, Inc.), anti-phosphorylated (p)-Akt (1:1,000; cat. no. 9271; Cell Signaling Technology, Inc.), anti-PTEN (1:1,000; cat. no. 9188; Cell Signaling Technology, Inc.), anti-MEK (1:1,000; cat. no. 8727; Cell Signaling Technology, Inc.), anti-ERK (1:1,000; cat. no. 4695; Cell Signaling Technology, Inc.), anti-p-ERK (1:1,000; cat. no. 4370; Cell Signaling Technology, Inc.), anti-Bax (1:1,000; cat. no. ab32503; Abcam), anti-Bcl-2 (1:1,000; cat. no. ab8227; Abcam).

Cell Counting Kit-8 (CCK-8) assay. CCK-8 regent (Dojindo Molecular Technologies, Inc.) was used to detect cell proliferation (24). At 48 h post-transfection, cells were seeded in a 96-well plate (4x10^3 cells/well). At each time point for detection (24, 48 and 72 h), cells were incubated with CCK-8 reagent at 37˚C for 2 h and the absorbance at 450 nm was measured.

Table I. Clinicopathological characteristics of patients with ccRCC.

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age, years</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>TNM stage</th>
<th>Tumor size, cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>52</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.7</td>
</tr>
<tr>
<td>2</td>
<td>66</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T2aN0M0</td>
<td>7.2</td>
</tr>
<tr>
<td>3</td>
<td>63</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.4</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>3.1</td>
</tr>
<tr>
<td>5</td>
<td>66</td>
<td>Female</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.6</td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>2.5</td>
</tr>
<tr>
<td>7</td>
<td>47</td>
<td>Female</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>3.2</td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.7</td>
</tr>
<tr>
<td>9</td>
<td>78</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.0</td>
</tr>
<tr>
<td>10</td>
<td>67</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>T2aN0M0</td>
<td>7.1</td>
</tr>
<tr>
<td>11</td>
<td>72</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>2.1</td>
</tr>
<tr>
<td>12</td>
<td>49</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>TaN0M0</td>
<td>2.5</td>
</tr>
<tr>
<td>13</td>
<td>47</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T2aN0M0</td>
<td>8.6</td>
</tr>
<tr>
<td>14</td>
<td>44</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T1bN0M0</td>
<td>4.7</td>
</tr>
<tr>
<td>15</td>
<td>53</td>
<td>Female</td>
<td>Left renal ccRCC</td>
<td>T3aN0M0</td>
<td>4.0</td>
</tr>
<tr>
<td>16</td>
<td>64</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T3aN0M0</td>
<td>5.0</td>
</tr>
<tr>
<td>17</td>
<td>50</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T1bN0M0</td>
<td>5.0</td>
</tr>
<tr>
<td>18</td>
<td>47</td>
<td>Male</td>
<td>Right renal ccRCC</td>
<td>T1bN0M0</td>
<td>7.0</td>
</tr>
<tr>
<td>19</td>
<td>50</td>
<td>Female</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>3.8</td>
</tr>
<tr>
<td>20</td>
<td>50</td>
<td>Female</td>
<td>Left renal ccRCC</td>
<td>T1bN0M0</td>
<td>4.5</td>
</tr>
<tr>
<td>21</td>
<td>62</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T1bN0M0</td>
<td>6.5</td>
</tr>
<tr>
<td>22</td>
<td>43</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>2.5</td>
</tr>
<tr>
<td>23</td>
<td>42</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>TaN0M0</td>
<td>3.0</td>
</tr>
<tr>
<td>24</td>
<td>53</td>
<td>Male</td>
<td>Left renal ccRCC</td>
<td>T1bN0M0</td>
<td>5.0</td>
</tr>
<tr>
<td>25</td>
<td>66</td>
<td>Female</td>
<td>Right renal ccRCC</td>
<td>T3aN0M0</td>
<td>3.5</td>
</tr>
</tbody>
</table>

ccRCC, clear cell renal cell carcinoma.
Colony formation assay. At 48 h post-transfection, cells were seeded in a 6-well plate (500 cells/well), cultured at 37°C in 5% CO₂ for 2 weeks, then fixed using 4% paraformaldehyde at room temperature for 15 min and stained with 0.5% gentian violet (Beyotime Institute of Biotechnology) at room temperature for 15 min. Clones consisting of ≥50 cells were counted under a light microscope (magnification, x40) (25,26).

5-Ethynyl-2'-deoxyuridine (EdU) staining. Cell proliferation was also analyzed using a Cell-Light EdU Apollo43 in vitro kit (cat. no. C10310-2; Guangzhou RiboBio Co., Ltd.), according to the manufacturer's protocol (27,28). A fluorescence microscope (Olympus Corporation) was used for analysis and images were obtained (magnification, x100).

Caspase-Glo assay. The activities of caspases-3, -7, -8 and -9 were measured using Caspase-Glo 3/7, 8 and 9 kits (cat. nos. G8090, G8200 and G8210, respectively; Promega Corporation), according to the manufacturer's protocol. Transfected cells were seeded (5x10⁵ cells/well) into a 96-well plate and incubated with Caspase-Glo reagents for 30 min. The luminescence was then detected with a microplate reader.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Transfected cells were seeded onto a climbing slide (5x10⁵ cells/well), cultured overnight and stained with a TUNEL reagent kit (In Situ Cell Death Detection kit, POD; cat. no. 11684817910; Roche Diagnostics) (29) at 37°C for 1-2 h and DAPI at 37°C for 5 min. Images were obtained using a fluorescence microscope (magnification, x100; Olympus Corporation).

Flow cytometry. To analyze the cell cycle, cells were suspended in PBS buffer at 48 h post-transfection, fixed in 75% ethanol at 4°C overnight and stained with propidium iodide (PI) at room temperature for 30 min. For the analysis of cell apoptosis, harvested cells were suspended in PBS and stained using an Annexin V-fluorescein isothiocyanate/PI kit (cat. no. 556570, FITC Annexin V Apoptosis Detection kit II, BD Biosciences). Following staining, cells were immediately detected using a flow cytometer (FACSCalibur; BD Biosciences), and analyzed with ModFit LT™ V3.3 (Verity Software House, Inc.) for cell cycle analysis and FlowJo 10 (FlowJo LLC) for apoptosis analysis (30,31).

Cell migration. Cell migration was evaluated using Transwell and wound-healing assays with the 786-O cell line. For the Transwell assay, 5x10⁴ cells suspended in 200 µl RPMI-1640 medium was added to the upper chamber and 700 µl complete medium was added to the lower chamber. After incubation for 48 h, the migrated cells were fixed. The fixed cells were then stained with crystal violet at room temperature for 15 min. The stained cells were viewed and counted in five random fields of view under an inverted phase contrast microscope (magnification, x200). For the wound-healing assay, the transfected cells were seeded in a 6-well plate (5x10⁵ cells/well). At confluence, the cell monolayer was scraped off and maintained in RPMI-1640. After 0, 24 and 48 h of incubation, an inverted microscope (magnification, x100) was used to capture the images.

Statistical analysis. Data were analyzed using SPSS 22.0 (IBM Corp.) and three independent experiments were performed. The data are presented as the mean ± standard deviation. CCK-8 and wound-healing results were statistically analyzed using two-way ANOVA. All other data were compared using unpaired Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

HOXA6 is downregulated in ccRCC specimens. The GSE6344 database contains ten paired ccRCC and normal tissues. The mRNA expression levels of HOXA6 were extracted from this database and analyzed. The results revealed that HOXA6 mRNA expression was significantly increased in normal tissues compared with in carcinoma tissues (Fig. 1A). Subsequently, GEPIA online analysis demonstrated that patients with lower expression levels of HOXA6 exhibited significantly poorer survival (Fig. 1B). Additionally, a total of 25 paired ccRCC and adjacent non-tumor specimens were analyzed by IHC. The majority of normal specimens (15/25) exhibited high expression levels of HOXA6, whereas the majority of tumor specimens (23/25) demonstrated low HOXA6 protein expression levels. HOXA6 was notably expressed in the nucleus of renal tubular epithelial cells. Furthermore, the protein expression levels of HOXA6 in normal tissues were significantly increased compared with in paired carcinoma tissues (Fig. 1C). These results suggest that HOXA6 protein expression is downregulated in ccRCC, which is in accordance with the findings of GSE6344 analysis.

Detection of HOXA6 expression in transfected cells. 786-O and 769-P cells were transfected with HOXA6 plasmid, empty vector, NC or shHOXA6, and HOXA6 expression was determined by RT-qPCR and western blotting. The results revealed that the expression of HOXA6 in 786-O and 769-P cells overexpressing HOXA6 was increased compared with the vector groups (RT-qPCR, P=0.0032 and P=0.0058; western blotting, P<0.001 and P=0.0020, respectively). Compared with the corresponding NC groups of 786-O and 769-P cells, HOXA6 expression in the shHOXA6 groups was significantly lower (RT-qPCR, P=0.0036 and P=0.0050; western blotting, P=0.0019 and P=0.0030, respectively; Fig. 1D). These results indicated that HOXA6 expression was successfully promoted and inhibited in the respective groups of transfected cells.

HOXA6 inhibits the proliferation of 786-O and 769-P cells. CCK-8, colony formation, EdU and flow cytometry assays were performed to determine the proliferation of transfected 786-O and 769-P cells. The CCK-8 assay revealed that HOXA6-overexpressing cells exhibited reduced proliferation compared with the vector groups (P<0.001), whereas the proliferation of cells expressing shHOXA6 significantly increased compared with the NC groups (P<0.001; Fig. 2A). In addition, fewer colonies in the HOXA6 overexpression groups (786-O, 95.67±11.71; 769-P, 143.33±10.02) were observed compared with the vector groups (786-O, 199.33±23.25, P=0.0066; 769-P, 189.33±17.04, P=0.0238); however, the number of colonies was significantly increased in the shHOXA6 groups (786-O, 306.00±22.72; 769-P,
compared with the corresponding NC groups (786-O, 196.33±17.67, P=0.0034; 769-P, 213.00±13.11, P=0.0071; Fig. 2B). Additionally, EdU staining revealed that, compared with the vector groups (786-O, 27.53±2.27%; 769-P, 34.24±1.28%), the proliferation of HOXA6-overexpressing cells (786-O, 18.44±2.26%, P=0.0079; 769-P, 15.52±2.07%, P=0.0015) was significantly inhibited. By contrast, the proliferation of the shHOXA6 groups (786-O, 48.41±1.94%; 769-P, 44.86±3.60%) was promoted compared with the corresponding NC groups (786-O, 28.19±2.28%, P<0.001; 769-P, 34.99±1.68%, P=0.0141; Fig. 2C). Furthermore, the cell cycle of transfected cells was analyzed by PI staining and flow cytometry. Compared with the vector groups, the number of G0/G1 phase cells was significantly increased in the HOXA6 overexpression groups (786-O, P=0.0072; 769-P, P=0.0380). By contrast, the number of G2/M phase cells was significantly
WU et al: HOXA6 AFFECTS CELL PROLIFERATION AND APOPTOSIS IN CCRCC

decreased in the shHOXA6 expression groups compared with the corresponding NC groups (786-O, P=0.0332; 769-P, P=0.0460; Fig. 2D). These results indicate that HOXA6 suppresses cell proliferation by inhibiting the cell cycle at the G0/G1 phase in ccRCC.

**HOXA6 induces the apoptosis of 786-O and 769-P cells.** Caspase-Glo, TUNEL and flow cytometry assays were performed to analyze the apoptosis of transfected cells. A Caspase-Glo assay was performed to detect the activities of caspases-3/7, -8 and -9. Compared with the vector group, the activities of caspases-3/7, -8 and -9 were significantly increased in the HOXA6-overexpressing 786-O and 769-P cell groups. By contrast, the activities of caspases-3/7 were significantly reduced in the shHOXA6-expressing 786-O and 769-P cell groups compared with the corresponding NC groups (Fig. 3A). The TUNEL assay also indicated that the apoptotic rates of the HOXA6 overexpression groups (786-O, 30.80±1.34%; 769-P; 26.72±1.28%) were significantly increased compared with the vector groups (786-O, 25.31±2.41%, P=0.0384;
However, the apoptotic rates were significantly decreased in the shHOXA6 groups (786-O, 17.61±2.82%; 769-P, 12.83±2.39%) compared with the corresponding NC groups (786-O, 24.31±1.30%, P=0.0372; 769-P, 22.92±0.58%, P=0.0141; Fig. 3B). In addition, flow cytometry was performed to analyze the apoptosis of transfected cells. The results revealed that, compared with the vector group, upregulation of HOXA6 significantly induced cell apoptosis (786-O, P=0.0067; 769-P, P=0.0027), while downregulation of HOXA6 suppressed apoptosis compared...
WU et al: HOXA6 AFFECTS CELL PROLIFERATION AND APOPTOSIS IN CCRC

with the corresponding NC groups (786-O, P=0.0475; 769-P, P=0.0418; Fig. 3C). These results demonstrated that HOXA6 could induce the apoptosis of ccRCC cells.

HOXA6 inhibits the PI3K/Akt signaling pathway. The expression levels of PI3K, Akt, p-Akt, phosphatase and tensin homolog (PTEN), MEK, ERK, p-ERK, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), Bcl-2, caspase-3, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) were analyzed by western blotting. The expression levels of PI3K, p-Akt, MEK, p-ERK and Bcl-2 were significantly suppressed in the HOXA6 overexpression groups, but were significantly upregulated following downregulation of HOXA6. The expression levels of PTEN, Bax, cleaved caspase-3 and cleaved PARP were significantly increased following HOXA6 overexpression compared with the vector group, but were significantly decreased in the shHOXA6 groups compared with the corresponding NC group (Fig. 4). These results suggest that HOXA6 inhibits cell proliferation and induces apoptosis via suppression of the PI3K/Akt signaling pathway.

HOXA6 inhibits the migration of 786-O cells. Cell migration was detected by Transwell and wound-healing assays. The Transwell assay results indicated that significantly fewer migrated cells were observed in the HOXA6 overexpression group compared with the vector group (P=0.0082). In addition, the number of migrated cells was significantly increased in the shHOXA6 group compared with the NC group (P=0.0023; Fig.5A). The wound-healing assay results revealed that compared with the vector group, the migration ability was
significantly reduced in the HOXA6-overexpressing cells (P<0.001). By contrast, the migration ability was significantly increased in the shHOXA6-expressing cells compared with the NC group (P<0.001; Fig. 5B).

**Discussion**

It has been reported that HOXA6 is upregulated in certain types of cancer and exhibits a role as an oncogene (13-15); however, studies have demonstrated that the CpG islands of HOXA6 are hypermethylated in malignant tumors (16,17). In addition, downregulated HOXA6 expression has been reported in breast cancer tissues (18); therefore, conflicting observations have been reported. In the present study, the expression of HOXA6 in ccRCC was downregulated. To further investigate this finding, the expression of HOXA6 in ccRCC microarrays from a GEO database was analyzed. The expression of HOXA6 mRNA was downregulated in cancer tissues in the GSE6344 dataset. To further verify these results, HOXA6 protein expression in ccRCC tissues was determined by IHC. The results revealed reduced expression of HOXA6 in cancer tissues compared with normal tissues. Furthermore, survival analysis was performed via GEPIA, which was based on data of The Cancer Genome Atlas. This analysis demonstrated that low expression of HOXA6 was associated with poor survival. The aforementioned results indicate that HOXA6 may serve a protective role in ccRCC. Furthermore, following the promotion or suppression of HOXA6 expression in ccRCC cells, alterations in cell proliferation and apoptosis were analyzed in the present study. CCK-8, colony formation, EdU staining and flow cytometry assays indicated that HOXA6 may suppress cell proliferation and inhibit the cell cycle at the G0/G1 phase. Caspase-Glo, TUNEL and flow cytometry assays further revealed that HOXA6 may promote cell apoptosis, and the activities of caspases-3/7, -8 and -9. However, a limitation of the present study is that a rescue experiment of apoptosis by HOXA6 was not performed.

The PI3K/Akt signaling pathway serves an important role in ccRCC for the regulation of cell proliferation, differentiation and survival. PTEN is a crucial inhibitor of the PI3K/Akt signaling pathway and functions as a tumor suppressor (32-34). In the present study, overexpression of HOXA6 promoted the expression of PTEN, leading to reductions in PI3K expression and Akt phosphorylation. p-Akt has a series of downstream effectors and is involved in various sub-pathways, including the mammalian target of rapamycin, glycogen synthase kinase 3, Bcl-2-associated death promoter, ERK, nuclear factor-κB and the c-Jun N-terminal kinase signaling pathways (35). The progression of the cell cycle from the G1 to S-phase is dependent on the activation of ERK (36). MEK is the upstream regulator of ERK, and can induce proliferation and inhibit apoptosis; thus, MEK may be a potential target of cancer therapy (37,38). The present study revealed that upregulation of HOXA6 led to reductions in the levels of p-Akt, increased the expression of MEK and suppressed the phosphorylation of ERK. The ERK signaling pathway has been reported to induce the anti-apoptotic properties of Bcl-2 (39). This supports the results of the present study as the expression of Bcl-2 was suppressed but that of Bax was increased, which leads to a decrease of the Bcl-2/Bax ratio following the upregulation of HOXA6. A decrease in the Bcl-2/Bax ratio has been negatively associated with cell apoptosis (40,41). Caspase-3 is the most important executioner of apoptosis, while PARP is an indicator of caspase-3 activation (42-44). The present study revealed that the protein expression levels of caspase-3 and PARP were upregulated in the HOXA6 group. These findings demonstrated that HOXA6 was involved in regulating cell proliferation and apoptosis, which may occur via the PI3K/Akt/ERK cascade in ccRCC cells.
In the present study, the expression of HOXA6 was suppressed in ccRCC tissues, which was associated with poor survival. In addition, it was identified that HOXA6 may be involved in regulating cell proliferation and apoptosis in ccRCC. Analysis of the pathways associated with these processes revealed that HOXA6 may be involved in the PI3K/Akt signaling pathway; however, the mechanism of how it regulates this pathway requires further investigation. The underlying mechanism of HOXA6 downregulation in ccRCC remains unknown; however, HOXA6 has been reported to be hypermethylated in meningiomas (17). Thus, further investigation is required to determine whether HOXA6 is hypermethylated in ccRCC and the additional roles of HOXA6 in this disease.

In summary, the present study reported that the expression of HOXA6 was downregulated in ccRCC and was negatively associated with the survival of patients. HOXA6 expression was determined to be associated with reduced cell proliferation and increased apoptosis, which may occur via inhibition of the PI3K/Akt/ERK pathway. These results indicate that HOXA6 may serve a role in the regulation of ccRCC; however, the underlying mechanism requires further investigation.

Acknowledgements

The authors would like to thank Dr Lixue Chen (The First Affiliated Hospital of Chongqing Medical University, Chongqing, China) for providing technical support.

Funding

The present study was supported by a grant from the Foundation of Chongqing Science and Technology Commission (grant no. cstc2015shmszx0466).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

FW made substantial contributions to the study conception, design, acquisition of data, analysis and interpretation of the data, and was involved in drafting the manuscript. SW and HT took part in the acquisition, analysis and interpretation of the data. WH and XG were involved in study conception, study design and revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was signed by all patients and ethics approval was obtained from the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


